Bausch Health Companies announced the U.S. launch of CABTREO Topical Gel, 1.2%/0.15%/3.1% indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. CABTREO Topical Gel is the first and only U.S. Food and Drug Administration-approved fixed-dose, once-daily triple-combination topical treatment for acne and offers three mechanisms of action, combining an antibiotic, retinoid and antibacterial, to provide a proven, safe and effective treatment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BHC:
- Bausch Health, Solta announce NMPA approval of Thermage FLX, TR-4 Return Pad
- Bausch Health reports Court of Appeals heard oral arguments on patent dispute
- Bausch Health put volume heavy and directionally bearish
- Bausch Health Companies (TSE:BHC) Surges after New Tests
- Bausch Health: Phase 2 study of Amiselimod meets primary, secondary endpoints